We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+12.05%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.07B
AUM Growth
-$249M
Cap. Flow
-$414M
Cap. Flow %
-13.47%
Top 10 Hldgs %
34.44%
Holding
117
New
6
Increased
34
Reduced
30
Closed
8

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$18.4M
2
ZBIO
Zenas BioPharma
ZBIO
+$15.8M
3
SMMT icon
Summit Therapeutics
SMMT
+$14.5M
4
NUVL
Nuvalent
NUVL
+$14.4M
5
CYTK icon
Cytokinetics
CYTK
+$11.5M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$168M
2
IDXX icon
Idexx Laboratories
IDXX
+$58.2M
3
EVH icon
Evolent Health
EVH
+$51.7M
4
BSX icon
Boston Scientific
BSX
+$28.2M
5
ACHC icon
Acadia Healthcare
ACHC
+$26.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.71%
2 Consumer Staples 1.99%
3 Financials 0.11%
4 Industrials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$376B
$172M 5.6%
294,250
+19,250
+7% +$10.9M
ISRG icon
2
Intuitive Surgical
ISRG
$127B
$133M 4.32%
270,000
-28,500
-10% -$13.3M
ARGX icon
3
argenx
ARGX
$53.4B
$127M 4.12%
233,500
+4,250
+2% +$2.15M
LLY icon
4
Eli Lilly
LLY
$1.02T
$126M 4.09%
142,000
+20,500
+17% +$18.4M
RARE icon
5
Ultragenyx Pharmaceutical
RARE
$2.45B
$110M 3.58%
1,978,272
+54,200
+3% +$2.76M
NBIX icon
6
Neurocrine Biosciences
NBIX
$16.8B
$108M 3.52%
939,000
-1,000
-0.1% -$137K
EXAS
7
DELISTED
Exact Sciences
EXAS
$78.2M 2.54%
1,147,500
+66,000
+6% +$3.72M
BPMC
8
DELISTED
Blueprint Medicines
BPMC
$71.1M 2.31%
768,776
-1,691,641
-69% -$168M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$27.5B
$68.8M 2.24%
250,000
– –
TVTX icon
10
Travere Therapeutics
TVTX
$5.2B
$65.5M 2.13%
4,684,476
+202,211
+5% +$2.11M
RYTM icon
11
Rhythm Pharmaceuticals
RYTM
$6.81B
$64.3M 2.09%
1,228,093
-52,400
-4% -$2.51M
MIRM icon
12
Mirum Pharmaceuticals
MIRM
$6.46B
$61.6M 2.01%
1,580,488
-191,550
-11% -$7.64M
FRPT icon
13
Freshpet
FRPT
$2.93B
$61.1M 1.99%
446,500
-33,500
-7% -$4.39M
EVH icon
14
Evolent Health
EVH
$348M
$58.5M 1.9%
2,070,000
-2,007,500
-49% -$51.7M
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$10.8B
$55.8M 1.82%
263,062
+17,563
+7% +$4.49M
PHR icon
16
Phreesia
PHR
$663M
$52M 1.69%
2,282,500
-135,000
-6% -$3.16M
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.06B
$51.8M 1.69%
1,316,477
+43,600
+3% +$1.76M
ACHC icon
18
Acadia Healthcare
ACHC
$2.76B
$51.7M 1.68%
815,000
-362,500
-31% -$26.2M
PEN icon
19
Penumbra
PEN
$12.7B
$51.5M 1.68%
265,000
– –
WST icon
20
West Pharmaceutical
WST
$24B
$50.4M 1.64%
167,750
+22,250
+15% +$6.81M
INSM icon
21
Insmed
INSM
$21.4B
$49.9M 1.62%
683,344
-125,012
-15% -$9.23M
KYMR icon
22
Kymera Therapeutics
KYMR
$8.51B
$49.7M 1.62%
1,049,386
-114,587
-10% -$5.06M
ASND icon
23
Ascendis Pharma A/S
ASND
$16B
$48.5M 1.58%
325,000
+35,000
+12% +$4.73M
HUM icon
24
Humana
HUM
$43.7B
$46.9M 1.53%
148,000
+592
+0.4% +$211K
GPCR icon
25
Structure Therapeutics
GPCR
$3.41B
$46.7M 1.52%
1,063,910
+64,048
+6% +$2.48M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Rock Springs Capital Management held 117 positions worth $3.07B, down 7.5% from $3.32B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management withdrew a net $414M in Q3 2024, closing 8 positions and reducing 30 holdings. Its most notable exit was Idexx Laboratories, an estimated $58.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rock Springs Capital Management opened a new position in Zenas BioPharma worth $14.9M.

  • Rock Springs Capital Management's largest Q3 2024 buy was Zenas BioPharma: 878,667 shares worth $14.9M.
  • Rock Springs Capital Management added most to Eli Lilly in Q3 2024, an estimated $18.4M increase.
  • Rock Springs Capital Management's biggest Q3 2024 reduction was Blueprint Medicines, cutting an estimated $168M.
  • Rock Springs Capital Management fully exited Idexx Laboratories in Q3 2024, selling an estimated $58.2M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $3.07B portfolio in Q3 2024.
  • Rock Springs Capital Management opened 6 new positions and closed 8 in Q3 2024.
  • Rock Springs Capital Management's portfolio value fell 7.5% quarter-over-quarter to $3.07B.

Based on Rock Springs Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.